ESCMID eAcademy

ePosters are only viewable by those with a valid ECCMID 2021 registration.
If you already have a registration, please login to the online platform here.
If you are not yet registered, you can do so here.
Abstract
Discussion Forum (0)
Abstract number: 95

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): P.M. Juiz (1), S. Méndez (1), I. Losada (2), N. Somaza (1), M. Rodríguez (3), G. Barbeito (4), F.J. Vasallo (5), M.I. Paz (6), F. García (7), M.V. Pulián (8), M. Serrano (9), J. Alba (10), P. Alonso (11), A. Agulla (1)

Authors Affiliations(s): (1) CHUF, Spain, (2) Servizo de Epidemioloxía, Spain, (3) CHUAC, Spain, (4) CHUS, Spain, (5) CHUVI, Spain, (6) CHUO, Spain, (7) HULA, Spain, (8) CHOP, Spain, (9) Hospital da Costa, Spain, (10) Hospital Comarcal do Barco de Valdeorras, Spain, (11) Hospital Comarcal de Monforte de Lemos, Spain

Background:

Vaccination against Streptococcus pneumoniae with polysaccharidic 23-valent antipneumococcal vaccine (PPSV23) was authorized in 2000 in Galicia (Spain) for ≥65 years-old belonging to risk groups. In 2001 vaccination with antipneumococcal 7-valent conjugated vaccine (PCV7) was authorized for children in risk groups. In 2011, systematic vaccination in children with antipneumococcal 13-valent conjugated vaccine (PCV13) was established. The aim of this study is to analyze the behavior of PCV13 and PPSV23 serotypes through the study period.

Methods:

Every invasive pneumococcal disease (IPD)-causing isolate in adults was collected from sterile bodily fluids (2088 samples) between 2011 and 2018. Serotyping was performed by latex agglutination and Quellung reaction (Statens Serum Institut latex/antisera, Copenhagen, Denmark). Incidences were described in cases/100,000 inhabitants.

Results:

IPD incidence has increased from 10,69 in 2011 to 15,55 in 2018. PCV13 incidence has decreased from 6,70 to 2,72, but non-PCV13/PPSV23 has increased from 1,83 to 8,43.

Regarding to PCV13/non-PCV7, serotype 3 has maintained its incidence, and serotypes 19A and 7F have decreased drastically. 1, 5 and 6A weren’t almost present from the beginning of the study. PCV7 were also less present, except 14 and 4, which decreased.

For PPSV23/non-PCV13, 12F, 9N and 22F have increased, and specially serotype 8, becoming the most prevalent in 2018 (29,72% of all cases). Data are shown in table below.

 

Conclusions:

After 8 years of systematic children vaccination with PCV13, IPD incidence in adults has increased, but PCV13-related IPD has decreased substantially.

There’s been an increase in the PPSV23 serotypes not included in PCV13, specially serotype 8, the most prevalent in 2018.

Keyword(s): Streptococcus pneumoniae, Vaccine

Abstract number: 95

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): P.M. Juiz (1), S. Méndez (1), I. Losada (2), N. Somaza (1), M. Rodríguez (3), G. Barbeito (4), F.J. Vasallo (5), M.I. Paz (6), F. García (7), M.V. Pulián (8), M. Serrano (9), J. Alba (10), P. Alonso (11), A. Agulla (1)

Authors Affiliations(s): (1) CHUF, Spain, (2) Servizo de Epidemioloxía, Spain, (3) CHUAC, Spain, (4) CHUS, Spain, (5) CHUVI, Spain, (6) CHUO, Spain, (7) HULA, Spain, (8) CHOP, Spain, (9) Hospital da Costa, Spain, (10) Hospital Comarcal do Barco de Valdeorras, Spain, (11) Hospital Comarcal de Monforte de Lemos, Spain

Background:

Vaccination against Streptococcus pneumoniae with polysaccharidic 23-valent antipneumococcal vaccine (PPSV23) was authorized in 2000 in Galicia (Spain) for ≥65 years-old belonging to risk groups. In 2001 vaccination with antipneumococcal 7-valent conjugated vaccine (PCV7) was authorized for children in risk groups. In 2011, systematic vaccination in children with antipneumococcal 13-valent conjugated vaccine (PCV13) was established. The aim of this study is to analyze the behavior of PCV13 and PPSV23 serotypes through the study period.

Methods:

Every invasive pneumococcal disease (IPD)-causing isolate in adults was collected from sterile bodily fluids (2088 samples) between 2011 and 2018. Serotyping was performed by latex agglutination and Quellung reaction (Statens Serum Institut latex/antisera, Copenhagen, Denmark). Incidences were described in cases/100,000 inhabitants.

Results:

IPD incidence has increased from 10,69 in 2011 to 15,55 in 2018. PCV13 incidence has decreased from 6,70 to 2,72, but non-PCV13/PPSV23 has increased from 1,83 to 8,43.

Regarding to PCV13/non-PCV7, serotype 3 has maintained its incidence, and serotypes 19A and 7F have decreased drastically. 1, 5 and 6A weren’t almost present from the beginning of the study. PCV7 were also less present, except 14 and 4, which decreased.

For PPSV23/non-PCV13, 12F, 9N and 22F have increased, and specially serotype 8, becoming the most prevalent in 2018 (29,72% of all cases). Data are shown in table below.

 

Conclusions:

After 8 years of systematic children vaccination with PCV13, IPD incidence in adults has increased, but PCV13-related IPD has decreased substantially.

There’s been an increase in the PPSV23 serotypes not included in PCV13, specially serotype 8, the most prevalent in 2018.

Keyword(s): Streptococcus pneumoniae, Vaccine

Streptococcus pneumoniae: serotype distribution in adults with invasive disease after 8 years of systematic vaccination of children with PCV13
Pedro Miguel Juiz González
Pedro Miguel Juiz González
ESCMID eAcademy. Juiz González P. 07/09/2021; 333194; 95
user
Pedro Miguel Juiz González
Abstract
Discussion Forum (0)
Abstract number: 95

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): P.M. Juiz (1), S. Méndez (1), I. Losada (2), N. Somaza (1), M. Rodríguez (3), G. Barbeito (4), F.J. Vasallo (5), M.I. Paz (6), F. García (7), M.V. Pulián (8), M. Serrano (9), J. Alba (10), P. Alonso (11), A. Agulla (1)

Authors Affiliations(s): (1) CHUF, Spain, (2) Servizo de Epidemioloxía, Spain, (3) CHUAC, Spain, (4) CHUS, Spain, (5) CHUVI, Spain, (6) CHUO, Spain, (7) HULA, Spain, (8) CHOP, Spain, (9) Hospital da Costa, Spain, (10) Hospital Comarcal do Barco de Valdeorras, Spain, (11) Hospital Comarcal de Monforte de Lemos, Spain

Background:

Vaccination against Streptococcus pneumoniae with polysaccharidic 23-valent antipneumococcal vaccine (PPSV23) was authorized in 2000 in Galicia (Spain) for ≥65 years-old belonging to risk groups. In 2001 vaccination with antipneumococcal 7-valent conjugated vaccine (PCV7) was authorized for children in risk groups. In 2011, systematic vaccination in children with antipneumococcal 13-valent conjugated vaccine (PCV13) was established. The aim of this study is to analyze the behavior of PCV13 and PPSV23 serotypes through the study period.

Methods:

Every invasive pneumococcal disease (IPD)-causing isolate in adults was collected from sterile bodily fluids (2088 samples) between 2011 and 2018. Serotyping was performed by latex agglutination and Quellung reaction (Statens Serum Institut latex/antisera, Copenhagen, Denmark). Incidences were described in cases/100,000 inhabitants.

Results:

IPD incidence has increased from 10,69 in 2011 to 15,55 in 2018. PCV13 incidence has decreased from 6,70 to 2,72, but non-PCV13/PPSV23 has increased from 1,83 to 8,43.

Regarding to PCV13/non-PCV7, serotype 3 has maintained its incidence, and serotypes 19A and 7F have decreased drastically. 1, 5 and 6A weren’t almost present from the beginning of the study. PCV7 were also less present, except 14 and 4, which decreased.

For PPSV23/non-PCV13, 12F, 9N and 22F have increased, and specially serotype 8, becoming the most prevalent in 2018 (29,72% of all cases). Data are shown in table below.

 

Conclusions:

After 8 years of systematic children vaccination with PCV13, IPD incidence in adults has increased, but PCV13-related IPD has decreased substantially.

There’s been an increase in the PPSV23 serotypes not included in PCV13, specially serotype 8, the most prevalent in 2018.

Keyword(s): Streptococcus pneumoniae, Vaccine

Abstract number: 95

Session Type: 1,5-hour Oral Session

Session Title: 1,5-hour Oral Session

Authors(s): P.M. Juiz (1), S. Méndez (1), I. Losada (2), N. Somaza (1), M. Rodríguez (3), G. Barbeito (4), F.J. Vasallo (5), M.I. Paz (6), F. García (7), M.V. Pulián (8), M. Serrano (9), J. Alba (10), P. Alonso (11), A. Agulla (1)

Authors Affiliations(s): (1) CHUF, Spain, (2) Servizo de Epidemioloxía, Spain, (3) CHUAC, Spain, (4) CHUS, Spain, (5) CHUVI, Spain, (6) CHUO, Spain, (7) HULA, Spain, (8) CHOP, Spain, (9) Hospital da Costa, Spain, (10) Hospital Comarcal do Barco de Valdeorras, Spain, (11) Hospital Comarcal de Monforte de Lemos, Spain

Background:

Vaccination against Streptococcus pneumoniae with polysaccharidic 23-valent antipneumococcal vaccine (PPSV23) was authorized in 2000 in Galicia (Spain) for ≥65 years-old belonging to risk groups. In 2001 vaccination with antipneumococcal 7-valent conjugated vaccine (PCV7) was authorized for children in risk groups. In 2011, systematic vaccination in children with antipneumococcal 13-valent conjugated vaccine (PCV13) was established. The aim of this study is to analyze the behavior of PCV13 and PPSV23 serotypes through the study period.

Methods:

Every invasive pneumococcal disease (IPD)-causing isolate in adults was collected from sterile bodily fluids (2088 samples) between 2011 and 2018. Serotyping was performed by latex agglutination and Quellung reaction (Statens Serum Institut latex/antisera, Copenhagen, Denmark). Incidences were described in cases/100,000 inhabitants.

Results:

IPD incidence has increased from 10,69 in 2011 to 15,55 in 2018. PCV13 incidence has decreased from 6,70 to 2,72, but non-PCV13/PPSV23 has increased from 1,83 to 8,43.

Regarding to PCV13/non-PCV7, serotype 3 has maintained its incidence, and serotypes 19A and 7F have decreased drastically. 1, 5 and 6A weren’t almost present from the beginning of the study. PCV7 were also less present, except 14 and 4, which decreased.

For PPSV23/non-PCV13, 12F, 9N and 22F have increased, and specially serotype 8, becoming the most prevalent in 2018 (29,72% of all cases). Data are shown in table below.

 

Conclusions:

After 8 years of systematic children vaccination with PCV13, IPD incidence in adults has increased, but PCV13-related IPD has decreased substantially.

There’s been an increase in the PPSV23 serotypes not included in PCV13, specially serotype 8, the most prevalent in 2018.

Keyword(s): Streptococcus pneumoniae, Vaccine

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies